Ramsankar Basak

Ramsankar Basak

Auto-generated profile, based on publicly available information

Ramsankar Basak

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2017 in JAMA
Verified
Journal Article
Open access
PDF file
RCRonald C. Chen
Ronald C. Chen
RBRamsankar Basak
Ramsankar Basak
AMAnne-Marie Meyer
Anne-Marie Meyer
TKTzy-Mey Kuo
Tzy-Mey Kuo
WCWilliam R. Carpenter
William R. Carpenter
PGPaul A. Godley
Paul A. Godley
The comparative effectiveness of contemporary treatment options for localized prostate cancer is one of the highest priority research questions according to the National Academy of Medicine (previously the Institute of Medicine).1 Because patients with prostate cancer often have extended life expectancy, the quality-of-life (QOL) effects of different treatment options is a central consideration for many men in their decision-making process.

25 May 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AFAaron D Falchook
Aaron D Falchook
SDStacie B Dusetzina
Stacie B Dusetzina
FTFang Tian
Fang Tian
RBRamsankar Basak
Ramsankar Basak
NSNandini Selvam
Nandini Selvam
RCRonald C. Chen
Ronald C. Chen
Aggressive medical care at the end of life can be harmful to patients and families, but its prevalence in use among younger cancer patients is unknown. The goal of the study was to report on the use of aggressive care and hospice services for patients younger than age 65 years. Using the HealthCore Integrated Research Database, we analyzed patients who died between 2007 and 2014 with metastatic lung (n = 12 764), colorectal (n = 5207), breast (n = 5855), pancreatic (n = 3397), or prostate (n = 1508) cancer. Based on published quality measures, we assessed uses of chemotherapy, intensive care, emergency room visits, and hospice care at the end of life. We examined additional items including radiotherapy, invasive procedures, hospitalization, and in-hospital deaths. Multivariable modified Poisson regression models were used to adjust for age, sex, geographic region, rural/urban location, year of death, and regional education and income measures. Across the five cancers, 10.1% to 14.1% of patients received chemotherapy within the last 14 days of life, 15.9% to 20.6% received intensive care in last 30 days, and 1.5% to 2.5% went to the emergency room two or more times in last 30 days. Hospice enrollment at least three days before death was 54.4% to 59.6%. However, 55.3% to 59.3% of patients had a hospital admission in the last 30 days, and one-third died (30.3%–35.4%) in the hospital. There was low use of cancer-directed treatment at the end of life for younger cancer patients, and hospice use was higher than 50%. However, there was a relatively high utilization of hospital-based care. These results demonstrate an opportunity for continued improvements in the provision of high-value, patient-centered care at the end of life.

1 January 2019 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
JTJustin G. Trogdon
Justin G. Trogdon
AFAaron D. Falchook
Aaron D. Falchook
RBRamsankar Basak
Ramsankar Basak
WCWilliam R. Carpenter
William R. Carpenter
RCRonald C. Chen
Ronald C. Chen
Importance Localized prostate cancer diagnosis and treatment among elderly men who are not likely to benefit represents a potential source of low-value health care services. Objective To quantify the costs to the Medicare program associated with detection and treatment of prostate cancer among elderly men in the United States. Design, Setting, and Participants This nationwide, population-based, retrospective cohort study uses the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to identify men 70 years or older diagnosed with localized prostate cancer between 2004 and 2007 and to ascertain Medicare costs associated with diagnosis and workup, treatment, follow-up, and morbidity management of the disease. National Medicare costs were estimated using per-person costs, stage-adjusted prostate cancer incidence rates by age from SEER 2007 through 2011, and 2010 Census population estimates by age. Main Outcomes and Measures Estimated costs to the Medicare program overall, and in each (mutually exclusive) category related to diagnosis and workup, treatment, follow-up, and morbidity management. Results This nationwide, population-based, retrospective cohort study included 49 692 men with nonmetastatic prostate cancer from the SEER-Medicare database (all participants were 70 years or older; 25 981 [52.3%] were 76 years or older). The median per-patient cost within 3 years after prostate cancer diagnosis was $14 453 (interquartile range [IQR], $4887-$27 899). The majority of this cost was attributable to treatment costs (median, $10 558; IQR, $1990-$23 718). Patients with a Gleason score of 6 or lower who pursued initial conservative management (no treatment within 12 months of diagnosis) had a 3-year median total cost of $1914 per patient. The estimated total 3-year cost to the Medicare program associated with the annual detection of prostate cancer in men 70 years or older is approximately $1.2 billion. Increasing active surveillance use in those with Gleason score of 6 or lower could reduce this cost by $320 million. Conclusions and Relevance There is substantial cost to the Medicare program associated with the diagnosis and treatment of localized prostate cancer among elderly men in the United States, despite the fact that these men are unlikely to die of prostate cancer. The majority of costs are related to treatment. Reducing provision of low-value health care services among this patient population could result in significant health care savings.


1 October 2012 in Population Health Management
Verified
Journal Article
Closed access
RKRahul Khanna
Rahul Khanna
PPPatrick F. Pace
Patrick F. Pace
RMRohan Mahabaleshwarkar
Rohan Mahabaleshwarkar
RBRam Sankar Basak
Ram Sankar Basak
MDManasi Datar
Manasi Datar
BBBenjamin F. Banahan
Benjamin F. Banahan
Limited information is currently available about medication adherence for common chronic conditions among the Medicaid population. The primary objective of this study was to assess medication adherence among Medicaid recipients with depression, diabetes, epilepsy, hypercholesterolemia, and hypertension. Factors influencing adherence were determined. The authors also assessed whether adherence influences the utilization of acute care services. The target population included nonelderly adult recipients (ages 21–64 years) who were continuously enrolled in the Mississippi (MS) Medicaid fee-for-service program from January 1, 2006 to December 31, 2007. Recipients were identified who had a medical services claim with a diagnosis of depression, diabetes, epilepsy, hypercholesterolemia, or hypertension in calendar year 2006. Within each chronic disease sample, medication adherence was determined using calendar year 2007 data for recipients who met inclusion and exclusion criteria. Recipients with adherence ≥80% were classified as adherent. Logistic regression analyses were used to determine the factors that predict medication adherence and the effect of adherence on concurrent all-cause acute care service (ie, hospitalization, emergency room visit) utilization. Approximately 24% of recipients with depression, 35.9% with diabetes, 53.6% with epilepsy, 32% with hypercholesterolemia, and 42.2% with hypertension were adherent. Within each chronic disease sample, males and whites had higher adherence than females and blacks. After controlling for demographic and disease-related covariates, recipients who were adherent had lower concurrent acute care service utilization than nonadherent recipients. Given the inverse relationship between adherence and acute care service utilization, policy makers should consider implementing educational interventions aimed at improving adherence in this underprivileged population. ( Population Health Management 2012;15:253–260)

1 March 2016 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
AFAaron D. Falchook
Aaron D. Falchook
NMNeil E. Martin
Neil E. Martin
RBRamsankar Basak
Ramsankar Basak
ASAngela B. Smith
Angela B. Smith
MMMatthew I. Milowsky
Matthew I. Milowsky
RCRonald C. Chen
Ronald C. Chen